Industry ties may play only a minor role in Robert Califf’s confirmation hearing for a second term as commissioner of the US Food and Drug Administration, though the issue is sure to be a rallying cry for any opposition to him.
President Biden’s decision to nominate Califf after a protracted search reflects in part a feeling that he will be confirmed by a wide margin – just like he was the last time. (See sidebar
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?